Background: Intravenous induction agents play a vital role in maintaining hemodynamic stability during general anesthesia. Propofol is commonly preferred because of its rapid onset and smooth recovery profile, although it frequently causes hypotension and cardiovascular depression. Etomidate is considered more hemodynamically stable and is often used in patients with compromised cardiovascular status. Aim: To assess and compare the hemodynamic changes and recovery profile following induction of general anesthesia using propofol and etomidate.Materials and Methods: A prospective comparative study was conducted among 120 adult patients undergoing elective surgeries under general anesthesia. Patients were randomly dividedinto two groups of 60 each. Group A received propofol 2 mg/kg intravenously, while Group B received etomidate 0.3 mg/kg intravenously for induction. Hemodynamic parameters including heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean arterial pressure (MAP) were recorded at baseline, after induction, and after intubation. Recovery profile and adverse effects were also evaluated.Results: Group B demonstrated significantly greater hemodynamic stability compared to Group A. The reduction in MAP after induction was significantly higher in Group A (p<0.001). Recovery time was shorter in Group A than Group B (p<0.05). Injection pain was more common in Group A, whereas myoclonus was observed predominantly in Group B.Conclusion:Etomidate provided superior hemodynamic stability during induction of general anesthesia, whereas propofol showed a faster recovery profile. Etomidate may be considered a safer induction agent in patients where cardiovascular stability is a major concern.
Dr. Payal Uikey, Dr. Pravin Kanoje, Dr. Syed Zeb Raza· Asian Journal of Medical Res...· 0 citations
Background: Spinal anesthesia using bupivacaine is widely employed for lower abdominal and lower limb surgeries. However, its limited duration of action often necessitates the use of adjuvants. Dexmedetomidine, a highly selective α2-adrenergic agonist, has shown promising results in prolonging sensory and motor blockade.Aim: To evaluate the efficacy of intrathecal dexmedetomidine as an adjuvant to bupivacaine in spinal anesthesia.Methods: A prospective comparative study was conducted on 80 patients randomly allocated into two groups. Group A received intrathecal hyperbaric bupivacaine alone, while Group B received bupivacaine combined with dexmedetomidine. Outcomes included onset time, duration of sensory and motor block, postoperative analgesia, and hemodynamic parameters.Results: The baseline demographic characteristics were comparable between the two groups, indicating no significant difference (p>0.05). The addition of dexmedetomidine significantly prolonged sensory and motor block duration and improved postoperative analgesia (p< 0.05) without major complications.VAS pain scores were consistently lower in Group B at all postoperative time intervals compared to Group A.Conclusion:Intrathecal dexmedetomidine is an effective and safe adjuvant to bupivacaine, enhancing the quality and duration of spinal anesthesia.
Dr. Syed Zeb Raza, Dr. Devesh Mishra, Dr. Payal Uikey· Asian Journal of Medical Res...· 0 citations